Biological activity of weekly ONC201 in adult recurrent glioblastoma patients

Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma

(2019) Seamus P. Caragher et al.   JOURNAL OF NEUROSCIENCE

First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report

(2019) Matthew D. Hall et al.   Journal of Neurosurgery-Pediatrics

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

(2019) Mark N. Stein et al.   Journal for ImmunoTherapy of Cancer

Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment

(2018) Jorge E. Romaguera et al.   BRITISH JOURNAL OF HAEMATOLOGY

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

(2018) Varun V. Prabhu et al.   CELL CYCLE

ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer

(2018) Avital Lev et al.   MOLECULAR CANCER RESEARCH

An active role for neurons in glioma progression: making sense of Scherer’s structures

(2018) Shawn Gillespie et al.   NEURO-ONCOLOGY

ONC201 kills breast cancer cells in vitro by targeting mitochondria

(2018) Yoshimi Endo Greer et al.   Oncotarget

Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor

(2018) Andrea A. Hayes-Jordan et al.   NEOPLASIA

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

(2018) Varun Vijay Prabhu et al.   CLINICAL CANCER RESEARCH

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

(2017) Marie D. Ralff et al.   MOLECULAR CANCER THERAPEUTICS

EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2

(2017) Andrew S Chi et al.   NEURO-ONCOLOGY

Monoamines in glioblastoma: complex biology with therapeutic potential

(2017) Seamus Patrick Caragher et al.   NEURO-ONCOLOGY

Dopamine receptor D2 is correlated with gastric cancer prognosis

(2017) Jiasheng Mu et al.   Oncology Letters

ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways

(2017) Xiao Ni et al.   Oncotarget

Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

(2017) Avital Lev et al.   Oncotarget

ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells

(2017) Xun Yuan et al.   Oncotarget

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

(2017) Isabel Arrillaga-Romany et al.   Oncotarget

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma

(2017) Yong-sheng Tu et al.   NEOPLASIA

The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent

(2016) Qiangbo Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice

(2016) Pouria Jandaghi et al.   GASTROENTEROLOGY

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

(2016) C. Leah B. Kline et al.   Science Signaling

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

(2016) C. Leah B. Kline et al.   Science Signaling

ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies

(2016) Jo Ishizawa et al.   Science Signaling

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10

(2015) J. E. Allen et al.   CANCER RESEARCH

Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner

(2015) V. V. Prabhu et al.   CANCER RESEARCH

ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells

(2015) Mala K Talekar et al.   CELL CYCLE

TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo

(2015) Georg Karpel-Massler et al.   Oncotarget

Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma

(2015) Jie Li et al.   Oncotarget

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

(2013) J. E. Allen et al.   Science Translational Medicine

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma

(2011) W. Wu et al.   NEURO-ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY